Sammaritano L R
Hospital for Special Surgery, Weill Medical College of Cornell University, 535 East 70th Street (777W), New York, NY 10021, USA.
Curr Rheumatol Rep. 2001 Jun;3(3):213-21. doi: 10.1007/s11926-001-0021-6.
Management of the pregnant patient with antiphospholipid antibody (aPL) is reviewed, with emphasis on recent randomized controlled clinical trials. These support the use of subcutaneous heparin and low dose aspirin, current standard therapy for women with aPL and a history of fetal loss. Prednisone is rarely used due to high risk of maternal and fetal morbidity. Intravenous immunoglobulin may represent an important additional therapy for women who fail aspirin and heparin. Patients with a history of thrombosis require full, therapeutic anticoagulation during pregnancy. Recommendations are less clear for newly described antibodies to phospholipid-binding protein, for low titer antibodies, and for infertility treatment in the setting of aPL.
本文回顾了抗磷脂抗体(aPL)阳性孕妇的管理,重点关注近期的随机对照临床试验。这些试验支持使用皮下肝素和低剂量阿司匹林,这是目前aPL阳性且有胎儿丢失史女性的标准治疗方法。由于母婴发病风险高,很少使用泼尼松。静脉注射免疫球蛋白可能是阿司匹林和肝素治疗无效女性的重要辅助治疗方法。有血栓形成史的患者在孕期需要进行充分的治疗性抗凝。对于新发现的磷脂结合蛋白抗体、低滴度抗体以及aPL情况下的不孕症治疗,相关建议尚不明确。